Stilcure Diethylstilbestrol Injection

DES Liquid Injection, Veterinary Products, Livestock Development

image of stilcure-des-inj-vet
DES is still sold under different names.

DES was sold under many names including Distilbène®, Stilbetin®, Stilboestrol-Borne®, Benzestrol®, Chlorotrianisene®, Estrobene® and Estrosyn® to name just a few.

Many different companies manufactured and marketed this drug under more than 200 different brand names.

This 10 ml Stilcure Diethylstilbestrol Injection USP is a current veterinary product.

DES Drugs Pictures
More DES DiEthylStilbestrol Resources

Foxd1 specific gene found to have key role in recurrent miscarriages

Possible miscarriage gene found

Scientists said they had linked mutations in a specific gene with an increased risk of recurrent miscarriages, offering hopes of better diagnosis and treatment for affected women.

Abstract

Recurrent spontaneous abortion (RSA) is a common cause of infertility, but previous attempts at identifying RSA causative genes have been relatively unsuccessful. Such failure to describe RSA aetiological genes might be explained by the fact that reproductive phenotypes should be considered as quantitative traits resulting from the intricate interaction of numerous genetic, epigenetic and environmental factors.

Association of FOXD1 variants with adverse pregnancy outcomes in mice and humans, The Royal Society Publishing, 19 October 2016.

Image James St. John.

Here, we studied an interspecific recombinant congenic strain (IRCS) of Mus musculus from the C57BL6/J strain of mice harbouring an approximate 5 Mb DNA fragment from chromosome 13 from Mus spretus mice (66H-MMU13 strain), with a high rate of embryonic resorption (ER). Transcriptome analyses of endometrial and placental tissues from these mice showed a deregulation of many genes associated with the coagulation and inflammatory response pathways. Bioinformatics approaches led us to select Foxd1 as a candidate gene potentially related to ER and RSA. Sequencing analysis of Foxd1 in the 66H-MMU13 strain, and in 556 women affected by RSA and 271 controls revealed non-synonymous sequence variants. In vitro assays revealed that some led to perturbations in FOXD1 transactivation properties on promoters of genes having key roles during implantation/placentation, suggesting a role of this gene in mammalian implantation processes.

Cancer du sein : en finir avec l’épidémie

André Cicolella pose le diagnostic d’une “crise sanitaire” liée à la toxicité de notre environnement

image du livre cancer-du-sein
Savoir affronter la dure réalité de la cancérologie du sein… a faire lire aux jeunes à titre préventif!

Cet essai d’André Cicollela, paru le 3 octobre 2016, propose une synthèse claire et accessible de l’état de la recherche scientifique sur le cancer du sein pour combattre les idées reçues : certes, certains cancers ont des causes génétiques, l’espérance de vie a augmenté et le dépistage s’est amélioré. Mais, quand on compare les taux de différents pays, on constate une très forte disparité liée aux modes de vie et aux facteurs de risques. Ainsi, d’après les bons résultats du Bhoutan, il serait théoriquement possible de réduire de 95 % le taux de cancer du sein en Belgique !

  • Pourquoi le nombre de cancers du sein dans le monde a-t-il doublé entre 1990 et 2013 ?
  • Pourquoi la Belgique connaît-elle 22 fois plus de cas que le Bhoutan ?
  • Pourquoi note-t-on des écarts importants entre pays de même niveau de développement, voire entre régions françaises ?
  • Pourquoi les jeunes femmes sont-elles de plus en plus touchées ?

S’appuyant sur les enquêtes scientifiques les plus récentes, André Cicolella passe au crible tous ces facteurs environnementaux, du DDT des années 1950 au bisphénol A aujourd’hui en passant par l’alimentation, la sédentarité ou les conditions de travail.

Il est temps de faire connaître les nombreuses données disponibles et de se mobiliser contre un étau qui nous touche tous, de près ou de loin. Si l’exposition au pesticide DDT a été reconnue cancérigène cinquante ans après les premières dénonciations, n’attendons pas cinquante autres années pour proscrire le bisphénol A et autres perturbateurs endocriniens de nos vies !

Des facteurs tels que le vieillissement de la population ou les progrès du dépistage n’expliquent que très partiellement l’épidémie qui touche toute la planète. Il n’y a pas de fatalité : si les cas de cancer du sein ont dramatiquement augmenté ces dernières décennies dans les pays occidentaux, c’est que les facteurs de risque présents dans notre environnement quotidien se sont multipliés.

La bonne nouvelle, c’est qu’il est possible de faire reculer l’épidémie, à condition de bien identifier ses causes et de mener les politiques publiques adéquates.

André Cicolella est chimiste toxicologue, ancien conseiller scientifique à l’Ineris et enseignant en santé environnementale à Sciences Po Paris. Il préside l’association Réseau environnement santé (RES), à l’origine de l’interdiction du bisphénol A dans les biberons et du perchloroéthylène pour le nettoyage à sec.

Apex Stilboestrol Tablets 1mg

DES Tablets, Veterinary Products, Male Dog Neutering

image of apex-stilboestrol-tablets
DES is still sold under different names.

DES was sold under many names including Distilbène®, Stilbetin®, Stilboestrol-Borne®, Benzestrol®, Chlorotrianisene®, Estrobene® and Estrosyn® to name just a few.

Many different companies manufactured and marketed this drug under more than 200 different brand names.

These Apex Stilboestrol tablets are current veterinary products.

DES Drugs Pictures
More DES DiEthylStilbestrol Resources

Regular Mammograms Risk-Benefit Characterization Theater

Breast-Cancer and Mammography : Consider the Pros and Cons

How Tiny Are Benefits From Many Tests And Pills? Researchers Paint A Picture

Mammograms are said to cut the risk of dying from breast cancer by as much as 20 percent ; some researchers want people to question that kind of thinking.

More Information

France: how to end breast cancer screening

The French national breast screening program is to be “radically revised”

In view of controversies surrounding the effectiveness and consequences of breast screening, the French Minister for Health asked the French National Cancer Institute (INCa) to organize a broad public and scientific consultation on breast cancer screening. During one year, all stakeholders on breast screening ranging from citizens, patient’s organisations and charities to health professionals, screening experts, and governmental institutions had an opportunity to express their opinion on the benefits and on the harms of breast screening as well as on the way this screening is organised in France. The consultation report was publicly available on September 30th, 2016.

Reduction in breast cancer deaths is due to treatment not screening, finds study, The BMJ, 355/bmj.i5544/rr-1, 13 October 2016.

The consultation report concludes that there is no scientific consensus about the benefits and risks of mammographic screening. It regrets the absence of sound epidemiological studies on the impact of breast screening in France. It expresses deep concerns about the

“malfunctions anomalies in the current organization of screening and the consequences it engenders: unequal access; lack of understanding of key concepts underpinning screening by most stakeholders; confusion between primary prevention, screening and early diagnosis; lack of information [of women] on risks and uncertainties of screening (…); lack of involvement of general practitioners (…); misleading and outrageous pink October marketing (…); doubts on the efficiency of some therapeutic strategies, etc.”

The report recommends that the information to women and the information and training of health professionals include a complete, clear and neutral information on the benefit and harm balance of participation to screening, with a depiction of reasons underlying the on-going scientific controversy.

It recommends discontinuing the reimbursement of mammographic screening in women less than 50 years of age at average risk of breast cancer. For healthy women over 50 years of age, the report recommends to take steps towards stratification of screening according to personal risk factors. Screening should be individualised, with the implication that women with low risk profile should not be offered mammographic screening. It also recommends that GPs should be integral part of the screening approach.

The options being considered for the future of screening are as follows:

  • Scenario 1: the end of organized screening, with the relevance of mammograms being evaluated in the context of an individual doctor patient relationship.
  • Scenario 2: the end of organized screening as now practiced, and the establishment of a new, radically altered form of organized screening. [i.e., much reduced]

The report is confident that

“the implementation of these recommendations should significantly improve the current situation, which currently does not meet the minimum requirements in terms of scientific validity and of information allowing women at average risk of breast cancer to take decisions”

The consultation report implicitly raises the question of whether the INCa would be the best placed for implementing recommendations and bring the radical changes in the breast screening programme. As a matter of fact, the INCa efforts have largely concentrated on maximizing participation to screening, the consequence of which has been the broadcasting of oversimplified messages insisting on the health benefits of screening while downplaying the undesirable effects like the overdiagnosis. In this regard, the INCa has backed the policy of financial incentives to GPs linked to their ability to convince women to participate to screening. Our opinion is that a neutral body should shape the breast screening programme, determine its main working procedures, and formulate the information to women and to health professionals. The members of this neutral body should have no academic or financial conflict of interest in relation to breast screening, and should not be involved in its implementation. We believe that such a move would be respectful of the consultation report conclusions and contribute to empowering women to decide on their participation to breast screening.

Jean Doubovetzky
Emilie Franzin
Marc Gourmelin
Philippe Nicot

On behalf of The Cancer-rose group.

Do breakfast cereals contain endocrine-disrupting pesticides?

EXPPERT Survey 7 – EDCs pesticides exposure ; what are the exposures in daily life?

The worrying results of Générations Futures EXPPERT survey 7 on a breakfast food, muesli, show the ubiquity of cocktails of hormone disrupting chemicals, also known as endocrine disrupting chemicals (EDCs) in the everyday environment. The findings highlight the need for the EU Commission to revise its recently proposed criteria to identify EDCs so that they become effective in protecting health.

Paris, Brussels, 11 October 2016 – The EXPPERT 7 report addresses exposure to EDCs in food eaten at breakfast, a meal considered essential. Food is one of the most important routes of exposure for anyone who is not regularly using pesticides.

The survey represents the seventh part in the EXPPERT series (EXposition aux Pesticides PERTurbateurs endocriniens) on endocrine-disrupting pesticides. It is an initiative of Générations Futures, France, in partnership with the Health and Environment Alliance (HEAL) and Pesticides Action Network Europe (PAN E).

EDC pesticides
EDCs are natural or artificial substances that are foreign to the human body. Exposure to these chemicals can interfere with the endocrine system and induce many adverse effects on an individual or on a person’s children or grandchildren. Many pesticides or biocides are either proven or strongly suspected to be EDCs.

Act now
To demonstrate the urgency of preventive action in the field of endocrine disruption, Générations Futures has produced a series of reports based on surveys and research analyses showing the omnipresence of many endocrine disruptors in our environment, which results in significant human exposure (these are the EXPPERT reports).

A targeted report
The 7th Exppert Report looks at one of the most important ways people who are not pesticide users get exposed: through food. Breakfast should meet a quarter of the body’s daily energy needs. This meal should include cereals, mixtures of which can be found in muesli. Générations Futures therefore focused on this popular consumer product – buying and analysing 15 packets of non-organic and five packets of organic cereal or muesli with fruit (or similar additions).

Results

100 percent of samples from the 15 non-organic products contained pesticide residues, including traces of suspected endocrine disrupting substances. None of the samples from the five organic packets contained pesticide residues.

Some figures:

  • In the 15 samples from non-organic packets tested, 141 residues were found, out of which the concentrations of 70 could be quantified. Of these 141 residues, 81 are suspected EDCs, equivalent to 57.44 percent of the total.
  • On average, 9.4 residues were found in the non-organic samples (the sample having the most residues contained 14 and those with the least had six). The non-organic samples had an average of 4.6 residues from suspected endocrine disrupting pesticides.
  • Of the 70 non organic samples that could be quantified, the average concentration of residues was 0.177 mg/kg per sample. This level is 354 times higher than the maximum allowable concentration (MAC) tolerated in drinking water for all pesticides!

“Each new report by our association has demonstrated the urgency to act. These findings again reveal population exposure to too many pesticide residues that are suspected of being endocrine disruptors, which can act at very low doses,”

says Francois Veillerette, spokesperson for Générations Futures.

“In June, the EU Commission announced its proposed criteria for determining EDCs but this definition is far from what is needed to protect the population’s health. The ubiquity of cocktails of EDCs in the environment is confirmed by this report. The findings must be taken into account by the EU Commission, which should revise its criteria to make them truly protective,”

he concludes.

Contacts
EXPPERT Surveys
  1. EXPPERT Survey 1: Which endocrine disrupting insecticides are children exposed to everyday? Press release, Brussels, 25 March 2013.
  2. EXPPERT Survey 2: Endocrine Disrupting Chemicals and banned Pesticides in strawberries. Press release, 25 March 2013.
  3. EXPPERT Survey 3: How are children exposed to Endocrine Disrupting Chemicals? Press release, 9 July 2014.
  4. EXPPERT Survey 4: Nineteen endocrine disrupting pesticides found in samples of women’s hair. Press release, 12 March 2015. Our blog.
  5. EXPPERT Survey 5: Pesticides that are banned or suspected to be EDCs are found in green salads. Press release, 22 September 2015. Our blog.
  6. EXPPERT Survey 6: Homes close to pesticide spraying show all year exposure. Press release, 1 March 2016. Our blog.
  7. EXPPERT Survey 7: Exposure to endocrine-disrupting pesticides. What are the exposures in daily life? Press release, 11 October 2016. Our blog.

Stilboestrol Dipropionate Injection

DES Liquid Injection, Veterinary Products, Livestock Development

image of Stilboestrol Dipropionate
DES is still sold under different names.

DES was sold under many names including Distilbène®, Stilbetin®, Stilboestrol-Borne®, Benzestrol®, Chlorotrianisene®, Estrobene® and Estrosyn® to name just a few.

Many different companies manufactured and marketed this drug under more than 200 different brand names.

This 10 ml Stilboestrol Dipropionate Injection is a current veterinary product.

DES Drugs Pictures
More DES DiEthylStilbestrol Resources

Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness

NEJM Screening Mammograms, Analysis by Dr. H. Gilbert Welch

Dr. H. Gilbert Welch gives us a brief explanation of the findings of the New England Journal of Medicine article “Breast Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness“, October 13, 2016.

Study Abstract

BACKGROUND
The goal of screening mammography is to detect small malignant tumors before they grow large enough to cause symptoms. Effective screening should therefore lead to the detection of a greater number of small tumors, followed by fewer large tumors over time.

METHODS
We used data from the Surveillance, Epidemiology, and End Results (SEER) program, 1975 through 2012, to calculate the tumor-size distribution and size-specific incidence of breast cancer among women 40 years of age or older. We then calculated the size-specific cancer case fatality rate for two time periods: a baseline period before the implementation of widespread screening mammography (1975 through 1979) and a period encompassing the most recent years for which 10 years of follow-up data were available (2000 through 2002).

RESULTS
After the advent of screening mammography, the proportion of detected breast tumors that were small (invasive tumors measuring

CONCLUSIONS
Although the rate of detection of large tumors fell after the introduction of screening mammography, the more favorable size distribution was primarily the result of the additional detection of small tumors. Women were more likely to have breast cancer that was overdiagnosed than to have earlier detection of a tumor that was destined to become large. The reduction in breast cancer mortality after the implementation of screening mammography was predominantly the result of improved systemic therapy.

There is no such thing as “free” vaccines…

Why Médecins Sans Frontières (MSF) rejected Pfizer’s donation offer of pneumonia vaccine (PCV) doses for the children they serve

Abstract

… “Free is not always better.

Donations often involve numerous conditions and strings attached, including restrictions on which patient populations and what geographic areas are allowed to receive the benefits. This process can delay starting vaccination campaigns, which would be an untenable situation in emergency settings, or grossly limit who you’re able to reach with the vaccine.

Donations can also undermine long-term efforts to increase access to affordable vaccines and medicines. They remove incentives for new manufacturers to enter a market when it’s absorbed through a donation arrangement. We need competition from new companies to bring down prices overall — something we don’t have currently for the pneumonia vaccine.

Donations are often used as a way to make others ‘pay up.’ By giving the pneumonia vaccine away for free, pharmaceutical corporations can use this as justification for why prices remain high for others, including other humanitarian organizations and developing countries that also can’t afford the vaccine. Countries, which continue to voice their frustration at being unable to afford new and costly vaccines such as PCV, need lower prices as well to protect children’s health.

Critically, donation offers can disappear as quickly as they come. The donor has ultimate control over when and how they choose to give their products away, risking interruption of programs should the company decide it’s no longer to their advantage. For example, Uganda is now facing a nationwide shortage of Diflucan, an essential crytpococcal meningitis drug, in spite of Pfizer’s commitment to donate the drugs to the government. There are other similar examples of companies’ donation programs leaving governments and health organizations in a lurch without the medical tools they need to treat patients.” …

… Read the full paper – There is no such thing as “free” vaccines: Why we rejected Pfizer’s donation offer of pneumonia vaccines, by Jason Cone, Executive Director of Doctors Without Borders in the United States, on medium.

  • More about the MSF Access Campaign, “pushing for access to & the development of life-saving and life prolonging medicines, diagnostic tests & vaccines for patients in MSF programmes and beyond“.
  • The Needle image by ps_sahana.